Capabilities

RHEI’s comprehensive capabilities provide foreign pharmaceutical and biotechnology companies with an efficient and cost effective way to bring proprietary products to the market in China. The Company’s core competencies in the areas of sales and marketing, regulatory and clinical development provide these pharmaceutical and biotechnology companies with a unique skill set and expertise not readily available.

RHEI’s strategy includes partnering with select Chinese pharmaceutical companies that are well regarded in RHEI’s core therapeutic focus areas, augmenting RHEI’s existing sales potential and marketing infrastructure with specialist teams.

Regulatory and Clinical Development
Outstanding access to top GCP clinical trial sites – In 2004, the State Food and Drug Administration (SFDA) issued a regulation stating that only Good Clinical Practice (GCP)-certified sites are authorized to conduct clinical trials. RHEI has ready access to these sites throughout China and its China-based team has extensive experience and a track record of success in designing and conducting clinical trials that meet international standards of practice.

Multi-layer drug protection strategy
RHEI understands the competitive landscape within the pharmaceutical industry and intellectual property is central to maximizing value. RHEI’s professionals work to properly protect pharmaceutical products in China and develop strategies to create an entry barrier for competitive products.

Sales and Marketing
National sales coverage in large volume Tier III hospitals and excellent presence in pharmacies– RHEI will build a sales and marketing team to cover Tier III hospitals, which are the largest and most sophisticated throughout China’s healthcare system. In its current stage this team interacts and works with preferred distribution partners who cover these hospitals as well as large pharmacy networks.

Influential government, medical community industry networks
RHEI employs a western-style approach to marketing and utilizes a proprietary network of advisors to help educate doctors and patients about novel therapies. RHEI’s own China-based senior management has experience in market research, sales force effectiveness and pharmaceutical product management.

Expansion to lower-tier hospitals
With the expansion of the middle class in China, smaller hospitals are becoming more advanced and the practice of medicine is becoming increasingly more sophisticated. RHEI is at the forefront of the industry expanding its reach to these smaller hospitals throughout the national healthcare system to expand the offering of modern medicine to the broader population.